Ipsen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

21.05.25	Ipsen S.A. - Annual General Meeting held on 21 May 2025 (GlobeNewswire)
12.05.25	Ipsen - April 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire)
21.02.25	Ipsen S.A. publishes its 2024 consolidated financial statements (GlobeNewswire)
11.06.24	FDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo (Benzinga)
10.03.23	Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire)
02.03.23	Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio (GlobeNewswire)
22.02.23	Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023 (GlobeNewswire)
15.02.23	Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs (GlobeNewswire)
13.02.23	Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma (GlobeNewswire)
27.01.23	Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U. (Businesswire)
20.01.23	Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI (Businesswire)
09.01.23	Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases (Businesswire)
23.12.22	Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva (Businesswire)
09.11.22	Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (Businesswire)
27.10.22	Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance (Businesswire)
25.10.22	Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting (Businesswire)
12.08.22	Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology (Businesswire)
05.08.22	Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022 (Businesswire)
03.08.22	Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer (Businesswire)
01.08.22	Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic (Businesswire)
29.06.22	Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission (Businesswire)
27.06.22	Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology (Businesswire)
09.06.22	Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults With Neurogenic Detrusor Overactivity Due to Multiple Sclerosis or Spinal Cord Injury (Businesswire)
01.06.22	Ipsen Initiates a Share Buy-Back Program to Cover Its Employee Free Share-Allocation Plan (Businesswire)
26.05.22	Ipsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer (Businesswire)
12.06.19	Debiopharm and Ipsen Extend Their Strategic Decapeptyl® (triptorelin) Partnership for Another 15 Years (Businesswire)
30.05.19	KNDL 2019-KNSQ Mortgage Trust -- Moody's assigns definitive ratings to Five CMBS classes of KNDL 2019-KNSQ Mortgage Trust (Moodys)
24.05.19	New Investigational Clinical Data for Ipsen’s Oncology Products in 11 Solid Tumor Types to Be Presented at 2019 ASCO Annual Meeting (Businesswire)
14.05.19	Ipsen to Host an Investor Day to Highlight Its Innovative R&D Pipeline and Provide Financial Outlook for 2022 (Businesswire)
08.05.19	KNDL 2019-KNSQ Mortgage Trust -- Moody's assigns provisional ratings to five CMBS classes of KNDL 2019-KNSQ Mortgage Trust (Moodys)
08.05.19	Moody's assigns provisional ratings to five CMBS classes of KNDL 2019-KNSQ Mortgage Trust (Moodys)
24.04.19	Ipsen Reports Strong Double-Digit Sales Growth in First Quarter 2019 and Confirms Full Year 2019 Financial Targets (Businesswire)
18.04.19	Ipsen Completes Acquisition of Clementia Pharmaceuticals (Businesswire)
25.02.19	Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion (Reuters)
04.06.18	Ipsen initiates a share buyback program to cover its free share allocation and employee share plans (Businesswire)
30.05.18	Combined Shareholders’ Meeting of IPSEN S.A. Held on 30 May 2018 (Businesswire)
30.05.18	IPSEN: Description of the Regulatory Framework of the Share Repurchase Program Proposed by the Board of Directors to Be Approved at the Combined Shareholders’ Meeting on 30 May 2018 (14th Resolution) (Businesswire)
29.05.18	Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development Partnership (Businesswire)
29.05.18	Ipsen Announces Clinical Data to Be Presented at ASCO Demonstrating Its Commitment to Patients with Cancer (Businesswire)
22.05.18	Ipsen launches employee share ownership plan (Businesswire)
17.05.18	European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the first-line treatment of adults with intermediate- or poor-risk advanced renal cell carcinoma (Businesswire)
26.04.18	Ipsen Reports Strong First Quarter 2018 Sales Growth of 23.1% at Constant Exchange Rates (Businesswire)
28.03.18	Ipsen Announces EMA Validation of Filing of a New Application for Additional Indication for Cabometyx®, for Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC) (Businesswire)
26.03.18	Ipsen Publishes Its 2017 Registration Document (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	26.52	1.18 %	K V
ABB	47.84	1.10 %	K V
CieFinRichemont	159.70	1.01 %	K V
Givaudan	4’167.00	0.82 %	K V
Geberit	606.20	0.66 %	K V
Alcon	71.96	-0.61 %	K V
Roche Hldg G	260.90	-0.61 %	K V
Sonova Hldg	263.10	-0.64 %	K V
Kuehne+Nagel Int	188.90	-0.76 %	K V
Zurich Insur Gr	582.00	-0.85 %	K V

Ipsen Aktie VALOR 2348805 / ISIN FR0010259150

Nachrichten zu Ipsen

Aktien Top/Flop

Meistgelesene Nachrichten